Life Extension Update
Friday, December 16, 2011. The results of a pilot study published in the November, 2011 issue of the Southern Medical Journal suggest a benefit for soy in men whose prostate cancer failed to respond to radiation or surgery.
The success of prostate cancer therapy is evaluated by measuring a protein known as serum prostate specific antigen (PSA). A rise in PSA following radiation or surgery for prostate cancer indicates treatment failure. An option for these patients is androgen deprivation therapy which reduces testosterone (a hormone that may increase the growth of prostate cancer); however, the treatment has significant side effects and is not effective for all who use it.
Monika Joshi, MD and her colleagues at Pennsylvania State University enrolled ten men with treatment-resistant prostate cancer that had not metastasized, and assigned them to three servings of soy per day for two years, during which PSA levels were monitored. After 24 months, half of the men showed a response to soy with temporary or permanently declining PSA levels or stable PSA levels. Of three subjects who were being treated with androgen deprivation therapy and continued to have rising PSA levels, one responded to soy, while four of the remaining seven showed favorable responses. The researchers remark that soy may reduce PSA via a reduction in the expression of the androgen receptor and other mechanisms.
"Our findings are fairly congruent with what has been described in the literature on the use of this modality in prostate cancer," the authors write. "We also show that soy can provide benefit in castration-resistant prostate cancer. Our clinical experience suggests that soy supplementation using commercially available soy products can have durable beneficial effects on PSA levels and PSA kinetics in some men with prostate cancer."
"The results from Pennsylvania State University appear consistent with a considerable amount of published research showing that soy may help to prevent prostate cancer and may be useful in its treatment," noted oncologist Omer Kucuk, MD, who is Georgia Cancer Coalition's distinguished cancer scholar and chief of genitourinary medical oncology at Emory University's Winship Cancer Institute. "For men unresponsive to surgery and radiation for prostate cancer, it is critically important to find androgen deprivation therapy alternatives, such as soy as a dietary intervention. While this study is small, it's important because it takes place in real-life conditions in a clinical setting."
UC-II® is a registered trademark of InterHealth Nutraceuticals, Inc. U.S. Patent Nos. 5,645,851, 5,637,321, 5,529,786, 5,750,144, 7,083,820, EP1485906 B1 and worldwide patents pending. AprèsFlex™ is a trademark of Laila Nutraceuticals exclusively licensed to PL Thomas – Laila Nutra LLC. International patents pending.
This supplement should be taken in conjunction with a healthy diet and regular exercise program. Individual results are not guaranteed and results may vary.
The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.
If you are not 100% satisfied with any purchase made directly from Life Extension®, just return your purchase within 12 months of original purchase date and we will either replace the product for you, credit your original payment method or credit your Life Extension account for the full amount of the original purchase price (less shipping and handling).
These statements have not been evaluated by the Food and Drug Administration.
These products are not intended to diagnose, treat, cure, or prevent any disease.